Rather, it appears to suppress AMPD2 expression, possibly leading to the elevated purine nucleotide synthesis and altered anti-inflammatory purinergic signaling, contributing to cytokine release syndrome and worsening disease severity in COVID-19 patients. This evidence concerns the gene AMPD2 and COVID-19.